Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.34 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185929 | 1.00 | PDE4D (0.34) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL3992645 | 1.00 | PDE4D (0.34) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL3992647 | 1.00 | PDE4D (0.34) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL4201627 | 0.94 | PTGDR2 (0.36) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL4201640 | 0.94 | PTGDR2 (0.36) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL4201637 | 0.94 | PTGDR2 (0.36) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL4201631 | 0.94 | PTGDR2 (0.36) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL3984970 | 0.86 | ALDH1A1 (0.42) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL3984972 | 0.86 | ALDH1A1 (0.42) | PDE4DKDM4EALDH1A1HKDC1TDP1 | |
| SCHEMBL4203760 | 0.86 | ALDH1A1 (0.42) | PDE4DKDM4EALDH1A1HKDC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009065081-A2 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | PDE4D 180/4885KDM4E 2807/4885ALDH1A1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.